Sure! Here's the new description with all links and additional text removed: --- Hot air balloon with marbles from copper ...

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to ...

Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.

Dr Reddy's Laboratories received a Form 483 with seven observations from the USFDA for its Srikakulam-based plant in Andhra ...

Enhance FDA compliance with our expanded training on inspection processes, common issues, and strategies for prevention. Gain insights into Form 483 and warning letter prevention, root cause ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in approval for deramiocel. Read more on CAPR stock here.

Emcure Pharma gets two observations for API plant from USFDA “We are addressing the observations comprehensively,” the company said.

USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of ...

On Friday, BTIG reaffirmed its Buy rating and $10.00 stock price target for Humacyte (NASDAQ:HUMA) following the release of a Form 483 from the FDA.

API manufacturer Global Calcium has been struck with a Form 483 filing following an FDA inspection of its factory in India.

Gland Pharma's Hyderabad facility gets 3 form 483 observations from USFDA This is the second surprise inspection the USFDA has carried out in a week.